Enzolytics Inc (ENZC)

[Mutat]

I believe Charles said this it March of this year and it clearly states we are further along with development to get a product to market than most realizes.

Mr. Cotropia:
We have a patented anti-HIV peptide, ITV-1, that has been tested in clinical studies. It is now being advanced through the next certification stage in preparation for patient application.
As a complementary treatment for HIV, we have created monoclonal antibodies for treating HIV. These antibodies can accurately be identified as being “fully human,” broadly neutralizing monoclonal antibodies in that the starting point is from human “immune-B cells,” providing the basis for the production of the antibodies. Antibodies created in this way retain the original natural antibody affinity and specificity and have a lower risk of immunogenicity when used as a therapeutic. They will provide broad-spectrum coverage against viral variants with increased potency and stability as a single-domain camelid molecule. Our technology then further stands out in that we are able to identify conserved, immutable sites on the targeted virus, and we have the ability to specifically create monoclonal antibodies that target these identified sites. The whole process is, in our view, a perfect approach to producing therapeutics that are safe and effective and that address and overcome the effect of virus mutation - all the while being able to be produced inexpensively, so they may be provided throughout the world.